A 26 week randomized, open label, multi-center study of the efficacy and safety of telbivudine 600 mg once daily versus adefovir dipivoxil 10mg once daily in subjects with compensated chronic hepatitis B and sub-optimal response to at least 48 weeks of adefovir dipivoxil 10 mg.

Trial Profile

A 26 week randomized, open label, multi-center study of the efficacy and safety of telbivudine 600 mg once daily versus adefovir dipivoxil 10mg once daily in subjects with compensated chronic hepatitis B and sub-optimal response to at least 48 weeks of adefovir dipivoxil 10 mg.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 01 May 2012

At a glance

  • Drugs Adefovir dipivoxil; Telbivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 May 2011 Planned end date changed from 1 Nov 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 07 Mar 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 29 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top